ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-OR95

Co-localization of IgG with Nephrin in Immune-Mediated Idiopathic Nephrotic Syndrome

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Inoki, Yuta, Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
  • Ichikawa, Yuta, Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
  • Sakakibara, Nana, Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
  • Kimura, Yuka, Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
  • Tanaka, Yu, Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
  • Ueda, Chika, Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
  • Kitakado, Hideaki, Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
  • Nagano, China, Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
  • Ishimori, Shingo, Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
  • Horinouchi, Tomoko, Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
  • Yamamura, Tomohiko, Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
  • Iijima, Kazumoto, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan
  • Nozu, Kandai, Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
Background

In minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS), increased serum anti-nephrin antibody titers and co-localization of nephrin and IgG in kidney tissues have been reported, indicating the involvement of anti-nephrin antibodies in nephrotic syndrome (NS). However, comprehensive studies on the association of kidney tissue-specific anti-nephrin antibodies in nephritis, including NS, are lacking.

Methods

To investigate the co-localization of IgG and nephrin, we included 52 kidney tissue samples, comprising NS in the acute phase (n = 25;MCD n=13, FSGS n=7, diffuse mesangial proliferation(DMP) n=5), NS in remission (n = 6), NS with monogenic variants (n = 3), and other kidney diseases (n = 18). The age of patients ranged from 0 to 88 years. We performed double-immunofluorescence staining of nephrin/IgG on unfixed frozen sections and subsequently evaluated the nephrin/IgG co-localization using optical sectioning in a fluorescence microscope.

Results

In acute phase NS, nephrin/IgG co-localization was observed in 80% (20/25) of cases. The proportions of observed nephrin/IgG co-localization were 88% (14 of 16) in pediatric cases (age at onset: 0-16 years) and 67% (6 of 9) in adult cases (age at onset: 47-88 years). Specifically, co-localization was observed in 85% (11 of 13) of MCD cases, 71% (5 of 7) of FSGS cases, and 80% (4 of 5) of DMP cases. Except for 1 case with NS in remission and 1 case with asymptomatic proteinuria (which later developed into NS and responded to steroids), co-localization was not observed in cases with NS in remission, NS with monogenic variants, or other kidney diseases.

Conclusion

In acute phase NS, nephrin/IgG co-localization was observed with high probability, strongly suggesting an association of anti-nephrin antibodies with the onset of idiopathic NS (INS). Staining of kidney tissue is fast, simple, and effective for investigating the pathogenesis of INS and for differential diagnosis of immune-mediated NS from other diseases, including genetic NS.